HCW Biologics Inc.
HCWB
$7.05
-$0.58-7.60%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -9.68% | 22.27% | 2.82% | 7.68% | -57.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.68% | 22.27% | 2.82% | 7.68% | -57.72% |
| Cost of Revenue | -29.55% | 3.49% | -11.54% | -2.57% | -44.83% |
| Gross Profit | 71.23% | 96.70% | 60.22% | 43.62% | -78.34% |
| SG&A Expenses | 29.22% | 130.50% | 178.49% | 123.15% | 121.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.21% | 67.34% | 75.84% | 43.11% | 31.00% |
| Operating Income | -14.63% | -73.59% | -90.08% | -50.07% | -70.55% |
| Income Before Tax | -20.12% | -89.19% | -105.09% | -52.90% | -67.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.12% | -89.19% | -105.09% | -52.90% | -67.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.12% | -89.19% | -105.09% | -52.90% | -67.74% |
| EBIT | -14.63% | -73.59% | -90.08% | -50.07% | -70.55% |
| EBITDA | -15.11% | -78.43% | -94.09% | -50.29% | -69.66% |
| EPS Basic | -13.24% | -82.70% | -99.19% | -51.04% | -67.24% |
| Normalized Basic EPS | -12.23% | -74.88% | -90.73% | -49.54% | -69.25% |
| EPS Diluted | -13.24% | -81.12% | -97.08% | -49.38% | -65.02% |
| Normalized Diluted EPS | -12.23% | -74.88% | -90.73% | -49.54% | -69.25% |
| Average Basic Shares Outstanding | 7.97% | 3.68% | 2.42% | 1.16% | 0.30% |
| Average Diluted Shares Outstanding | 7.97% | 3.68% | 2.42% | 1.16% | 0.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |